This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
22 Mar 2012

UCB Pharma with Oxford University to Develop Drugs for Serious Diseases

UCB will fund the collaboration with ?3.6 million over three years to develop medicines that will treat serious diseases in immunology and neurology.

UCB Pharma and the University of Oxford in the UK will jointly develop medicines that will treat serious diseases in immunology and neurology. A steering committee of UCB and Oxford University representatives will oversee the collaboration via regular meetings to scope out and monitor new projects.

 

UCB, which has already invested heavily in research and development in the UK, will fund the collaboration with £3.6 million over three years. Between five and ten projects will be selected for investigation over the course of the agreement.

 

UCB chief executive Roch Doliveux said, "This new partnership combines Oxford University's world-class academic research with UCB's world-class antibody research

Related News